Bluebird widens hunt for TCR therapies in revised Medigene deal

Bluebird bio on Monday said it has expanded a 2016 research partnership with German biotech Medigene, signaling greater interest in the development of T cell receptor (TCR)-based immunotherapies to complement its existing efforts around CAR-T technology.